Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library
Authors:
- Ivette Mendoza-SalazarIMIvette Mendoza-Salazar
- Keyla M. Gómez-CastellanoKGKeyla M. Gómez-Castellano
- Edith González-GonzálezEGEdith González-González
- Ramsés Gamboa-SuasnavartRGRamsés Gamboa-Suasnavart
- Stefany D. Rodríguez-LunaSRStefany D. Rodríguez-Luna
- Giovanni Santiago-CasasGSGiovanni Santiago-Casas
- María I. Cortés-PaniaguaMCMaría I. Cortés-Paniagua
- Sonia M. Pérez-TapiaSonia M. Pérez-Tapia
- Juan C. AlmagroJAJuan C. Almagro
Open Access
- 10 February 2022
- journal article
- research article
- Published by MDPI AG in Antibodies
- Vol. 11 (1) , 13
Abstract
This report describes the discovery and characterization of antibodies with potential broad SARS-CoV-2 neutralization profiles. The antibodies were obtained from a phage display library built with the VH repertoire of a convalescent COVID-19 patient who was infected with SARS-CoV-2 B.1.617.2 (Delta). The patient received a single dose of Ad5-nCoV vaccine (Convidecia™, CanSino Biologics Inc.) one month before developing COVID-19 symptoms. Four synthetic VL libraries were used as counterparts of the immune VH repertoire. After three rounds of panning with SARS-CoV-2 receptor-binding domain wildtype (RBD-WT) 34 unique scFvs, were identified, with 27 cross-reactive for the RBD-WT and RBD Delta (RBD-DT), and seven specifics for the RBD-WT. The cross-reactive scFvs were more diverse than the RBD-WT specific ones, being encoded by several IGHV genes from the IGHV1 and IGHV3 families combined with short HCDR3s. Six cross-reactive scFvs and one RBD-WT specific scFv were converted to human IgG1 (hIgG1). Out of the seven antibodies, six blocked the RBD-WT binding to angiotensin converting enzyme 2 (ACE2), suggesting these antibodies may neutralize the SARS-CoV-2 infection. Importantly, one of the antibodies also recognized the RBD from the B.1.1.529 (Omicron) isolate, implying that the VH repertoire of the convalescent patient would protect against SARS-CoV-2 Wildtype, Delta, and Omicron. From a practical viewpoint, the triple cross-reactive antibody provides the substrate for developing therapeutic antibodies with a broad SARS-CoV-2 neutralization profile.Keywords
This publication has 33 references indexed in Scilit:
- Phage Display Libraries for Antibody Therapeutic Discovery and DevelopmentAntibodies, 2019
- VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine designCurrent Opinion in Virology, 2019
- ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discoverymAbs, 2019
- Structural diversity in a human antibody germline librarymAbs, 2016
- High-Throughput Melting-Temperature Analysis of a Monoclonal Antibody by Differential Scanning Fluorimetry in the Presence of SurfactantsJournal of Pharmaceutical Sciences, 2013
- Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline GenesPLOS ONE, 2012
- Natural and man-made V-gene repertoires for antibody discoveryFrontiers in Immunology, 2012
- Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering2011
- Rare antibodies from combinatorial libraries suggests an S.O.S. component of the human immunological repertoireMolecular BioSystems, 2011
- Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodiesMolecular Immunology, 1987